Cell and gene therapy

The Cell and Gene Therapy Catapult (CGT Catapult) has published new data in their 2021 Cell and Gene Therapy GMP manufacturing report and 2021 UK cell and gene therapy skills demand report. These reports highlight the continued growth across the UK’s Advanced Therapy Medicinal Product (ATMP) manufacturing capacity and strong demand for highly skilled personnel […]

The Cell and Gene Therapy (CGT) Catapult has today published its Annual Review 2021, highlighting its key initiatives and impact in creating opportunities and investment in the UK cell and gene therapy industry.  2021 has reportedly emphasised the strength of the UK cell and gene therapy industry which experienced significant expansion despite the Covid-19 pandemic. The UK […]

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening.  Alain Parthoens, Ncardia’s Chairman, said: “Kiniciti is uniquely suited to help Ncardia expand globally and to […]

The Cell and Gene Therapy Catapult (CGT Catapult) and Deep Science Ventures have partnered to address barriers in the ATMP industry, create new companies and deliver better patient outcomes.  Recent advances in cell and gene therapies promise potential cures to devastating diseases. However, major hurdles still need to be overcome, including ensuring target specificity and effective manufacturing […]

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.  The funding will also support the continued […]

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis.  LR: What was the thinking behind the Collective? […]

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale.   Ibrahim Baylan, the Swedish Minister for Business, […]

MiroBio has appointed Carolin Barth as CEO to lead the company through the next major stage of its growth as its lead programme, MB272, transitions into clinical development. Dr Barth’s appointment follows other recent senior appointments including Julian Hirst, formerly of Immunocore, as CFO and Lynne Murray, formerly of AstraZeneca, as Senior VP of R&D.  […]

BioIVT’s human AB serum product line is designed to supplement cell culture media and facilitate cell and gene therapy development.  Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human AB serum produces biologically relevant conditions that allow many human cell lines […]

Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency of cell and gene therapies for use within its point-of-care […]